PD-L1, a key inhibitory immune receptor, has crucial functions in cancer immune evasion,
but whether PD-L1 promotes the malignant properties of cervical cancer (CC) cells and the …

A better understanding of the mechanisms underlying PD‐L1 aberrant expression in head
and neck squamous cell carcinoma (HNSCC) will help reveal predictive biomarkers and …

Abstract Programmed death-ligand 1 (PD-L1) has been reported to be expressed in many
types of tumor cells, and bind to PD-1 on T lymphocytes to inhibit immune response …

Abstract Programmed death-ligand 1 (PD-L1) is expressed in various immune cells and
tumor cells, and is able to bind to PD-1 on T lymphocytes, thereby inhibiting their function. At …

PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment.
However, low response rates suggest that patient selection based on PD-L1 protein …

Some studies imply that LINC00116 is involved in cervical cancer progression; however, the
molecular mechanism by which LINC00116 modulating tumorigenesis of cervical cancer …

Cancer immunotherapy has many great achievements in recent years. One of the most
promising cancer immunotherapies is PD-1/PD-L1 pathway blockade. miRNAs (MicroRNAs) …

Upregulation of programmed death 1 ligand 1 (PD-L1) in cancer cells and its ligation to PD-
1 on T cells facilitates cancer cell escape from immune surveillance. Therapies with PD-1 or …

The present study is to measure the expression of programmed death‐1 (PD‐1) and
programmed death ligand‐1 (PD‐L1), as well as its clinical significance in cervical cancer …

Cancer immunotherapy is a growing field nowadays. Among different molecular pathways,
PD-1/PD-L1 signaling pathway plays a significant role in the regulation of immune …